Clinical Trial Update: Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating BIIB021 in combination with exemestane (Aromasin) for hormone receptor-positive metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromasin (exemestane)
• BIIB021 (BIIB021)

Snippet

Sponsor: Biogen | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED